Found 898 with Last Name = 'saunders' and Initial = 'jo' TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 5nM ΔG°: -46.9kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 10nM ΔG°: -45.2kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 11nM ΔG°: -45.0kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 13nM ΔG°: -44.6kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
Affinity DataKi: 17nM ΔG°: -43.9kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 27nM ΔG°: -42.8kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 27nM ΔG°: -42.8kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 28nM ΔG°: -42.7kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 33nM ΔG°: -42.3kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
3D Structure (crystal)Affinity DataKi: 43nM ΔG°: -41.6kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 55nM ΔG°: -41.0kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 56nM ΔG°: -41.0kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
Affinity DataKi: 90nM ΔG°: -39.8kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 200nM ΔG°: -37.9kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 200nM ΔG°: -37.9kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 530nM ΔG°: -35.5kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
Affinity DataKi: 700nM ΔG°: -34.8kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 800nM ΔG°: -34.4kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 800nM ΔG°: -34.4kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 1.20E+3nM ΔG°: -33.5kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 1.30E+3nM ΔG°: -33.3kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 1.90E+3nM ΔG°: -32.3kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 2.00E+3nM ΔG°: -32.2kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: >3.00E+3nM ΔG°: >-31.2kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17 [215-477,S266A,N452Q](Homo sapiens (Human))
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Affinity DataKi: 3.40E+3nM ΔG°: -30.9kJ/molepH: 7.5 T: 2°CAssay Description:The compounds were tested for TACE inhibition using fluorescence resonance energy transfer (FRET) assay. TACE catalyzed cleavage of the substrate pep...More data for this Ligand-Target Pair
Affinity DataKi: 3.40E+3nM ΔG°: -30.9kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 5.00E+3nM ΔG°: -30.0kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 5.70E+3nM ΔG°: -29.6kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: >6.00E+3nM ΔG°: >-29.5kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
Affinity DataKi: 3.30E+4nM ΔG°: -25.3kJ/molepH: 7.4 T: 2°CAssay Description:A continuous assay was used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin), which is quenched by en...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IDH1 R132H mutant in human Neurospheres assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of wild type IDH1/IDH1 R132H mutant heterodimer (unknown origin) after 16 hrs in presence of NADPH by diaphorase/resazurin coupled fluores...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of IDH1 R132G mutant (unknown origin)More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of wild type IDH1/IDH1 R132H mutant heterodimer (unknown origin) after 60 mins in presence of NADPH by diaphorase/resazurin coupled fluore...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of IDH1 R132H mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of IDH1 R132S mutant in human HCCC-9810 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of IDH1 R132S mutant (unknown origin)More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of IDH1 R132L mutant (unknown origin)More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of IDH1 R132C mutant (unknown origin) assessed as reduction in conversion of alpha-KG to D2-HG after 60 mins in presence of NADPH by diaph...More data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of IDH1 R132C mutant in human HT1080 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
TargetIsocitrate dehydrogenase [NADP] cytoplasmic(Homo sapiens (Human))
Agios Pharmaceuticals
Curated by ChEMBL
Agios Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of IDH1 R132C mutant in human COR-L105 cells assessed as reduction in 2-hydroxyglutarate production by LC-MS/MS analysisMore data for this Ligand-Target Pair
